Loading…

An end stage kidney disease predictor based on an artificial neural networks ensemble

► We use an artificial neural networks (ANNs) ensemble to classify patients’ health status potentially leading to end stage kidney disease (ESKD). ► Development based on the largest available cohort worldwide for ESKD with data collected over a period of forty years. ► Evaluation of the classificati...

Full description

Saved in:
Bibliographic Details
Published in:Expert systems with applications 2013-09, Vol.40 (11), p.4438-4445
Main Authors: Di Noia, Tommaso, Ostuni, Vito Claudio, Pesce, Francesco, Binetti, Giulio, Naso, David, Schena, Francesco Paolo, Di Sciascio, Eugenio
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:► We use an artificial neural networks (ANNs) ensemble to classify patients’ health status potentially leading to end stage kidney disease (ESKD). ► Development based on the largest available cohort worldwide for ESKD with data collected over a period of forty years. ► Evaluation of the classification results based on precision, recall and F-measure. ► Development of a RESTful application to deliver the risk prediction service; both a Web client and an Android application are available for direct evaluation. IgA Nephropathy (IgAN) is a worldwide disease that affects kidneys in human beings and leads to end-stage kidney disease (ESKD) thus requiring renal replacement therapy with dialysis or kidney transplantation. The need for new tools able to help clinicians in predicting ESKD risk for IgAN patients is highly recognized in the medical field. In this paper we present a software tool that exploits the power of artificial neural networks to classify patients’ health status potentially leading to ESKD. The classifier leverages the results returned by an ensemble of 10 networks trained by using data collected in a period of 38years at University of Bari. The developed tool has been made available both as an online Web application and as an Android mobile app. Noteworthy to its clinical usefulness is that its development is based on the largest available cohort worldwide.
ISSN:0957-4174
1873-6793
DOI:10.1016/j.eswa.2013.01.046